Efficacy and safety of loteprednol etabonate 0.5% gel in the treatment of ocular inflammation and pain after cataract surgery
Authors:
- Rajesh K. RajpalRRRajesh K. Rajpal
- Lawrence RoelLRLawrence Roel
- Raphaele Siou-MermetRSRaphaele Siou-Mermet
- Tara ErbTETara Erb
- 1 February 2013
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Cataract & Refractive Surgery
- Vol. 39 (2) , 158-167
Abstract
To examine the efficacy and safety of a new gel formulation loteprednol etabonate 0.5% in the treatment of inflammation and pain after cataract surgery. Seventeen United States clinical sites. Prospective double-masked parallel-group study. Patients with anterior chamber cell (ACC) grade 2 or higher after cataract surgery were randomized to loteprednol etabonate 0.5% gel or vehicle 4 times a day for 14 days. Primary outcome measures included the proportion of patients with complete resolution of ACC and grade 0 (no) pain on postoperative day 8. Safety measures included adverse events, intraocular pressure (IOP), visual acuity, biomicroscopy and funduscopy findings, and tolerability (ocular symptoms and drop comfort). The intent-to-treat population included 406 patients (203 per treatment). On day 8, 30.5% of patients in the loteprednol etabonate group and 16.3% of patients in the vehicle group had complete resolution of ACC, whereas 72.9% and 41.9%, respectively, had grade 0 pain (both P<.001). Significant treatment differences for complete resolution of ACC and grade 0 pain favoring loteprednol etabonate were also found on day 15 and day 18. One patient in each treatment group had a significant increase in IOP (≥ 10 mm Hg). Analyses of pain, photophobia, and tearing favored loteprednol etabonate at different time points beginning on day 3. More than 85% of patients in each treatment group reported no discomfort on drop instillation. Loteprednol etabonate gel 0.5% was efficacious and safe in treating postoperative inflammation and pain. Dr. Rajpal is a consultant to Bausch & Lomb, Inc., Allergan, Inc., and Alcon Laboratories, Inc. Dr. Siou-Mermet and Ms. Erb are employees of Bausch & Lomb, Inc. Dr. Roel has no financial or proprietary interest in any material or method mentioned.Keywords
This publication has 15 references indexed in Scilit:
- Topical Loteprednol Pretreatment Reduces Cyclosporine Stinging in Chronic Dry Eye DiseaseJournal of Ocular Pharmacology and Therapeutics, 2011
- Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and painJournal of Cataract & Refractive Surgery, 2009
- Control of intra-ocular inflammation associated with cataract surgeryCurrent Opinion in Ophthalmology, 2001
- Control of intraocular inflammation associated with cataract surgeryCurrent Opinion in Ophthalmology, 2000
- Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitisAmerican Journal of Ophthalmology, 1999
- Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5 for postoperative inflammationJournal of Cataract & Refractive Surgery, 1998
- A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation, ,Ophthalmology, 1998
- A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitisJournal of Allergy and Clinical Immunology, 1998
- Control of ocular inflammation after cataract extraction with rimexolone 1% ophthalmic suspensionJournal of Cataract & Refractive Surgery, 1997
- Ocular pressure response to fluorometholone acetate and dexamethasone sodium phosphateCurrent Eye Research, 1984